Insulet’s Growth Spurt Meets Modular’s Regulatory Push -( $PODD $MODD $ABT $DXCM )

Insulet’s (PODD) latest run of press releases reads like a victory lap for a company that has turned tubeless insulin delivery into a global franchise, while Modular Medical (MODD) is quietly trying to crash or expand the same party with a stripped‑down, value‑oriented, easier to use Pivot Patch Pump now stepping into the regulatory spotlight. In diabetes tech terms, Insulet is hosting the conference and Modular is slipping in through the side door with an IRB badge and a 510(k) file folder.

Insulet: podium position in patch pumps

Over its last three communications, Insulet has sketched a familiar but enviable picture: Omnipod 5 driving double‑digit top‑line growth, a widening global footprint, and enough investor confidence to justify a dedicated Investor Day at headquarters. Third‑quarter results showed Omnipod sales climbing roughly 30% year over year to just under $700 million, prompting yet another bump to full‑year revenue guidance and reinforcing Insulet’s status as the category’s scale incumbent.

Strategically, management is signaling that this is not just a pump company, but a consumer‑health platform wrapped around a pod, with expansion into new geographies and additional non‑insulin indications part of the longer‑term roadmap. The upcoming Investor Day is billed as a showcase for that evolution—part factory tour, part strategy seminar, and part reminder that Insulet’s moat is measured in installed base, data, and distribution, not just plastic and electronics.

Omnipod 5: the high‑end benchmark

Operationally, Omnipod 5 remains the product to beat, combining automated insulin delivery with tight CGM integration and a fully tubeless, wearable format that Insulet continues to roll out across North America and Europe. In markets like the U.K., Netherlands, and Canada, the system now pairs with both Dexcom (DXCM) and Abbott (ABT) sensors, giving prescribers and patients the rare luxury of choice in a segment where hardware ecosystems typically demand monogamy.

That combination of algorithmic automation, broad age indications, and smartphone control helps explain why analysts remain comfortable underwriting 20‑plus percent growth off an already large base. It also sets the competitive bar: any challenger patch pump must either offer a meaningfully better experience or a meaningfully lower cost—ideally both—just to get a hearing from payers and clinicians already invested in the Omnipod infrastructure.

Modular’s Pivot: the budget disruptor

Enter Modular Medical’s (MODD) Pivot tubeless patch pump, which has now cleared two key milestones in less than a week: FDA 510(k) submission and Institutional Review Board approval for an in‑house insulin delivery study using the commercial‑form device. The company is explicitly aiming at what it calls the “almost‑pumper” segment (~$3B opportunity)—insulin users who have balked at legacy systems on complexity or cost—by promising a simpler, more affordable patch pump with a removable three‑milliliter reservoir and a two‑part, detachable design.

The near‑term plan is straightforward: gather real‑world usability and performance data under IRB oversight while the FDA digests the 510(k), and prepare manufacturing so that, in a best‑case scenario, commercial launch could follow in early 2026. Importantly, the company is careful to note that Pivot is not yet cleared for sale, underscoring that execution risk still sits squarely with regulators and the company’s ability to scale production and convert those “almost‑pumpers” into paying customers.

Two patch pumps, one crowded lane

From a market‑structure perspective, Insulet and Modular are nominally in the same business—tubeless insulin delivery—but increasingly targeting different corners of the runway. Insulet is optimizing a premium, feature‑rich ecosystem that leans into CGM partnerships, software updates, and international expansion; Modular is positioning Pivot as the minimalist alternative for patients who just want reliable basal and bolus delivery without a graduate degree in diabetes tech.

If Insulet wins by deepening engagement with existing pump users and expanding globally, Modular’s opportunity lies in expanding the total patch‑pump pie by converting injections to pumps in a cost‑conscious cohort that has historically been under‑served. Whether that turns into a complementary dynamic or a competitive collision will depend on how aggressively payers push for lower‑priced options once Pivot is, if ever, on the formulary menu.

Investor angle: incumbents vs insurgents

For investors, the setup resembles a familiar medtech narrative: a scaled incumbent delivering clean beats, margin expansion, and a well‑telegraphed capital‑allocation framework, while a micro‑cap insurgent courts attention with regulatory catalysts and promises of a cheaper mousetrap. Insulet’s near‑term story hinges on sustaining mid‑20s revenue growth and translating Omnipod scale into operating leverage, themes likely to be front and center at the November 20 Investor Day.

Modular Medical (MODD), by contrast, is still in the proving‑ground phase where each press release—an FDA submission here, an IRB approval there—serves as both scientific milestone and investor‑relations oxygen. In a market where tubeless pumps have already gone mainstream, Pivot doesn’t need to dethrone Omnipod so much as demonstrate that there is room, and reimbursement, for a second act in patch‑pump innovation—this time aimed squarely at those who have been almost, but not quite, ready to take the plunge.

Insulet: podium position in patch pumps

Omnipod 5: the high‑end benchmark

Modular’s Pivot: the budget disruptor

Two patch pumps, one crowded lane

Investor angle: incumbents vs insurgents

The Sources..

Related

You May Also Like

Oklo’s Innovative Fast Reactor Seeks To Power U.S. Clean Energy Future with DOE Support – ( $OKLO $XLE )

Inside InterGroup’s Fiscal 2025: Hotel Profits Surge, Real Estate Rises, Stock Recovers -( $INTG )

Your Guide To Staying Informed In The Markets